IDXX
Idexx LaboratoriesNASDAQHealth CareDiagnostics & ResearchSnapshot 2026-05-08
As of May 8, 2026, IDXX has a composite score of 22.5 and a signal label of "mild favorable." The score is influenced by a medium confidence level of 75.4 and is driven by factors such as macroeconomic conditions related to labor, rates, growth, and inflation. The current assessment is provisional.
Price
Daily closes from AlphaVantage. Earnings/event dots are placed inline.
Factor signals
Read top-to-bottom: thesis (is this a strong company over a 1–3 year hold), watch flags (has something changed worth re-reading), and position context (how violent might the path be). Each pill is a parallel diagnostic — never aggregated into a single score.
Thesis
— is this a strong company over a 1–3 year hold?Why this rank
- Direction share1.00
- Slope (norm)-0.22
- Bonus0.00
Why this rank
Trailing four: 2024-Q3, 2025-Q1, 2025-Q2, 2025-Q3
Why this rank
Watch
— has something changed worth re-reading?Why this setup
EPS estimate $3.94 → $3.94 (-0.1% / 30d). 1 raised, 0 cut, 12 covering analysts.
0 upgrades, 0 downgrades / 30d, 1 maintained. 60% of analysts rate Buy.
1 PT revisions / 30d. Avg target 12.4% above current price.
0 positive, 0 negative / 30d.
F4 · Management deep-dive — recent events, stated priorities, guidance track record
Recent 8-K events
5 material events in the last 24 months — top 5 listed below.
Stated priorities
2 priorityies extracted from earnings transcripts (as of 2026-05-08).
- 1.Increase 2026 revenue guidancegrowthmixed63% progress
5/5: “Increases 2026 revenue guidance to $4,675 million - $4,760 million, up $42 million or ~1% at midpoint.”
Why this status
Stated in 2 of last 2 quarters. Revenue guidance increased from $4,632 million to $4,675 million, reflecting a $43 million increase. The trajectory shows management's confidence in stronger CAG Diagnostics recurring revenue performance.
- 2.Raise 2026 EPS outlookgrowthbehind0% progress
5/5: “Raises 2026 EPS outlook to $14.45 - $14.90, reflecting an increase of $0.13 compared to prior guidance midpoint.”
Why this status
Stated in 2 of last 2 quarters. EPS guidance increased from $14.29 to $14.45, reflecting a $0.16 increase. This aligns with management's expectations for increased revenue and comparable operating margin expansion.
Guidance track record
Insufficient guidance history for this ticker.
Position context
— how violent might the path be while I hold it?Why this risk level
Recent vol — 30d annualized 30%; 252d 39%.
Drawdown — Max 1y −28%. Bad day move −3%.
Beta to sector ETF (XLV) — 0.94 over 1y.
Liquidity — score 100/100.
Sub-scores — vol 35/100, drawdown 44/100, beta 94/100, earnings vol —.
Calm + bullish setup — clean pre-earnings positioning pattern.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive — historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only — describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-05-08.
What changed
The most important moves since the prior daily snapshot.
- No material changes since the prior snapshot.
No material changes since the prior snapshot.
as of 2026-05-08
Management scorecard
How management runs the business — capital, margins, balance sheet, and how reliably they guide and deliver.
What management is focused on
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
- #1
Increase 2026 revenue guidance
GrowthNew since 2026-05-05Management has increased the 2026 revenue guidance to $4,675 million - $4,760 million.
MixedStated in 2 of last 2 quarters. Revenue guidance increased from $4,632 million to $4,675 million, reflecting a $43 million increase. The trajectory shows management's confidence in stronger CAG Diagnostics recurring revenue performance.
63%CEO/CFO:“Increases 2026 revenue guidance to $4,675 million - $4,760 million, up $42 million or ~1% at midpoint.”Multiple sourcesSource dated 2026-05-05Stated 2 of last 8 quartersFirst seen 2026-05-05Show history (2)
- 2026-Q1Multiple sources
“Increases 2026 revenue guidance to $4,675 million - $4,760 million.”
- 2025-Q4Multiple sources
“Provides initial outlook for 2026 revenue guidance range of $4,632 million - $4,720 million.”
- #2
Raise 2026 EPS outlook
GrowthNew since 2026-05-05Management has raised the 2026 EPS outlook to $14.45 - $14.90.
BehindStated in 2 of last 2 quarters. EPS guidance increased from $14.29 to $14.45, reflecting a $0.16 increase. This aligns with management's expectations for increased revenue and comparable operating margin expansion.
0%CEO/CFO:“Raises 2026 EPS outlook to $14.45 - $14.90, reflecting an increase of $0.13 compared to prior guidance midpoint.”Multiple sourcesSource dated 2026-05-05Stated 2 of last 8 quartersFirst seen 2026-05-05Show history (2)
- 2026-Q1Multiple sources
“Raises 2026 EPS outlook to $14.45 - $14.90.”
- 2025-Q4Multiple sources
“Projects 2026 EPS of $14.29 - $14.80.”
How this stock is priced
Two ways to read price: against peers in the same business, and against the company's own history.
Looks more expensive than peers.
Cheaper than its own typical valuation.
P/E over the last 5 years
71 monthly pointsHow this compares
A side-by-side read on composite, valuation, and risk versus peers.
| Stock | Composite | Valuation | Risk |
|---|---|---|---|
IDXX Idexx Laboratories | +23 | full | moderate |
LLY Lilly (Eli) | +21 | full | moderate |
JNJ Johnson & Johnson | +18 | full | low |
ABBV AbbVie | +12 | fair | low |
UNH UnitedHealth Group | +24 | fair | elevated |
Risk — how this stock moves
What a normal day looks like, what a bad day looks like, and the worst the last year has thrown at it.
What could change this view
Conditional scenarios — if X happens, the score would shift by about Y points. These are not predictions.
- If health_care sector trend rises from +0.06 into 'improving' (>= +0.20)+5.0 pts
- If next-quarter guidance is cut (currently RAISED as of 2026-05-05)-16 pts
- If labor state reverses from -0.31 (negative) to +0.31 (positive)-6.8 pts
- If health_care sector trend falls from +0.06 into 'weakening' (<= -0.20)-5.0 pts
- If rates state reverses from -0.37 (negative) to +0.37 (positive)-2.9 pts
Material updates
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
- 2026-05-053d agoItem 2.02
shall be deemed to be furnished, and not filed. Exhibit No. Description of Exhibit 99.1 Press Release entitled “IDEXX Laboratories Announces First Quarter Results,” issued by the Company on May 5, 2026. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IDEXX LABORATORIES,…
earnings preannouncementneutralscore 61 - 2026-03-261mo agoItem 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On March 24, 2026, IDEXX Laboratories, Inc. (“IDEXX”) and Nimrata Hunt, PhD, Executive Vice President, Global Strategy and Commercial, mutually agreed that Dr. Hunt will cease serving in her current role effective on April 13, 2026 (the “Separation Date”) and will continue to provide advisory services on an as-needed basis until July 13, 2026 (the “…
executive changeneutralscore 21 - 2026-02-132mo agoItem 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (b) On February 13, 2026, Ms. M. Anne Szostak provided IDEXX Laboratories, Inc. (the “Company”) notice of her intention to retire from the Board of Directors (the “Board”) effective immediately following the Company’s 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”) to be held on May 12, 2026. Ms. Szostak’s decision to retire from th…
executive changeneutralscore 8 - 2026-02-023mo agoItem 2.02
shall be deemed to be furnished, and not filed. Exhibit No. Description of Exhibit 99.1 Press Release entitled “IDEXX Laboratories Announces Fourth Quarter and Full Year 2025 Results,” issued by the Company on February 2, 2026. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly auth…
earnings preannouncementneutralscore 7
Score history
The composite score, snapshot by snapshot. The dotted line at zero separates leaning-positive from leaning-negative.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.